Lippis Daniel J.'s Form 4 filing
Edwards Lifesciences Corp (EW) · filed May 9, 2024
- Accession no.
- 0001225208-24-005890
- Filed
- May 9, 2024
- Trade date
- May 7, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 5 non-derivative transactions and 3 derivative transactions. Open-market sales total $73.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Lippis Daniel J.CIK 0002004380 | Officer (CVP, JAPAC) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2024 | Common Stock | AGrant or awardAcquired | +4,660 | $0.00 | $0 | 21,575.74 | Direct | |
| May 7, 2024 | Common Stock | AGrant or awardAcquired | +2,900 | $0.00 | $0 | 24,475.74 | Direct | |
| May 7, 2024 | Common Stock | MOption exerciseAcquired | +857 | $36.75 | +$31,494.75 | 25,332.74 | Direct | |
| May 7, 2024 | Common Stock | FTax withholdingDisposed | −586 | $85.09 | −$49,862.74 | 24,746.74 | Direct | |
| May 7, 2024 | Common Stock | SSaleDisposed | −857 | $85.60 | −$73,359.2 | 23,889.74 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 7, 2024 | Common Stock | AGrant or awardAcquired | +15,500 | $0.00 | $0 | 15,500 | Direct | |
| May 7, 2024 | Common Stock | MOption exerciseDisposed | −857 | $0.00 | $0 | 0 | Direct | |
| May 7, 2024 | Common Stock | AGrant or awardAcquired | +2,900 | $0.00 | $0 | 2,900 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.
Remarks
This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person.